Novel NLRP3 Inhibitors for Steroid Resistant Asthma

哮喘每年导致40,000人住院，其中5-10%的哮喘患者患有严重的类固醇抗性哮喘，这是一种常见的使人衰弱的疾病，目前的治疗方法不起作用。迫切需要有效的治疗方法。根据我们的研究，我们有新的分子在严重类固醇抗性哮喘模型中显示出高水平的疗效。这些分子将被进一步研究，以在3年内提供一种候选药物进行商业化。

Asthma causes 40,000 hospitalisations p.a. with 5-10% of asthmatics having severe steroid resistant asthma, a common and debilitating disease, where current treatments do not work. Effective therapies are urgently required. Based on our research, we have novel molecules showing high level of efficacy in models of severe steroid resistant asthma. These molecules will be further investigated to deliver a drug candidate for commercialisation within 3 years.